HEPA
Income statement / Annual
Last year (2024), Hepion Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Hepion Pharmaceuticals, Inc.'s net income was -$13.19 M.
See Hepion Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$26.74 K
|
$18.79 K
|
$21.94 K
|
$0.00
|
$21.53 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$26.74 K
|
-$18.79 K
|
-$21.94 K
|
$0.00
|
-$21.53 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11.85 M
|
$35.64 M
|
$33.27 M
|
$20.40 M
|
$12.00 M
|
$3.18 M
|
$7.59 M
|
$14.33 M
|
$13.65 M
|
$15.02 M
|
| General & Administrative Expenses |
$7.50 M
|
$9.62 M
|
$10.35 M
|
$10.01 M
|
$8.15 M
|
$4.59 M
|
$7.00 M
|
$7.28 M
|
$7.37 M
|
$5.79 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$583.71 K
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.50 M
|
$9.62 M
|
$10.35 M
|
$10.01 M
|
$8.15 M
|
$4.59 M
|
$7.00 M
|
$6.69 M
|
$7.37 M
|
$5.79 M
|
| Other Expenses |
$0.00
|
$3.19 M
|
$1.87 M
|
$0.00
|
$0.00
|
$0.00
|
-$108.94 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$19.35 M
|
$48.45 M
|
$45.49 M
|
$30.40 M
|
$20.15 M
|
$7.77 M
|
$14.59 M
|
$21.02 M
|
$21.02 M
|
$20.81 M
|
| Cost And Expenses |
$19.35 M
|
$48.45 M
|
$45.49 M
|
$30.40 M
|
$20.15 M
|
$7.77 M
|
$14.59 M
|
$21.04 M
|
$21.02 M
|
$20.81 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$1.25 M
|
$9.47 K
|
$10.16 K
|
$8.86 K
|
$31.23 K
|
$555.00 K
|
$339.16 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$30.76 K
|
$67.13 K
|
$77.46 K
|
$86.07 K
|
$34.52 K
|
$26.74 K
|
$18.79 K
|
$21.94 K
|
$27.99 K
|
$21.53 K
|
| EBITDA |
-$14.88 M |
-$49.26 M |
-$45.00 M |
-$32.63 M |
-$20.11 M |
-$7.74 M |
-$14.58 M |
-$20.62 M |
-$21.02 M |
-$20.81 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.18 M
|
-$887.11 K
|
$404.83 K
|
-$2.32 M
|
-$177.28 K
|
-$175.94 K
|
$4.61 M
|
$2.13 M
|
$4.22 M
|
$3.81 M
|
| Income Before Tax |
-$16.16 M
|
-$49.34 M
|
-$45.08 M
|
-$32.72 M
|
-$20.32 M
|
-$7.95 M
|
-$9.99 M
|
-$18.92 M
|
-$16.80 M
|
-$17.00 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$2.97 M
|
-$409.02 K
|
-$2.88 M
|
$0.00
|
$30.58 K
|
-$908.68 K
|
-$536.00 K
|
-$3.90 M
|
-$1.91 M
|
$0.00
|
| Net Income |
-$13.19 M
|
-$48.93 M
|
-$42.20 M
|
-$32.72 M
|
-$20.35 M
|
-$7.04 M
|
-$9.45 M
|
-$15.02 M
|
-$14.89 M
|
-$17.00 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-107.348 |
-616.0715 |
-594.75 |
-465.52 |
-2103.7 |
-6108.07 |
-97353 |
-106400 |
-2855.94 |
-352800 |
| EPS Diluted |
-107.348 |
-616.0715 |
-594.75 |
-465.52 |
-2103.7 |
-6108.07 |
-97353 |
-106400 |
-3373.93 |
-352800 |
| Weighted Average Shares Out |
$122.89 K
|
$79.42 K
|
$76.23 K
|
$70.29 K
|
$9.68 K
|
$2.04 K
|
$183.88
|
$138.26
|
$5.20 K
|
$48.32
|
| Weighted Average Shares Out Diluted |
$122.89 K
|
$79.42 K
|
$76.23 K
|
$70.29 K
|
$9.68 K
|
$2.04 K
|
$183.88
|
$138.26
|
$5.21 K
|
$48.32
|
| Link |
|
|
|
|
|
|
|
|
|
|
